PURPOSE: In the present study, the combination of @entity3003 ( @entity3003 ) plus pemetrexed (PMX) for the treatment of @entity1 with @entity902 -pretreated, pemetrexed-na  ve, advanced @entity1149 ( @entity1149 ) was investigated. Also, single nucleotide polymorphisms (SNPs) at the @entity20823 , @entity4735 , @entity11833 , GARFT, DHFR, and @entity1950 genes were investigated. METHODS: Eighty @entity1 treated with @entity3003 /PMX at two Italian institutions were evaluable. Of these, 73 @entity1 had blood samples collected for pharmacogenetic evaluation. RESULTS: Overall, the median age was 59 years (26-78), 59 @entity1 (73.7%) had a performance status of 0, and 34 @entity1 (42.5%) had stage IIIB disease. Thirty-eight @entity1 (47.5%) had responded to prior first-line @entity902 -based therapy. Study treatment resulted into one complete and 33 partial responses for an overall response rate of 42.5%. The disease control rate was 77.5%. The median progression-free survival (PFS) and overall survival (OS) were 5.8 and 17.4 months, respectively. Responders achieved a significant longer PFS and OS versus non-responders (P = 0.007 and P = 0.003, respectively). The only grade 3-4 adverse event occurring in more than 5.0% of @entity1 was @entity1398 (6 @entity1 , 7.5%). No statistically significant association was noted between polymorphisms of the genes analyzed and clinical outcome. CONCLUSIONS: In @entity1 with @entity902 -pretreated, advanced @entity1149 and favorable clinical prognostic factors, treatment with @entity3003 /PMX is associated with a good clinical outcome and @entity137 profile. None of the SNPs analyzed was found to be a useful predictor of treatment efficacy.

XXXX plus pemetrexed for @entity902 -pretreated, advanced @entity1149 : a retrospective study with pharmacogenetic evaluation.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity11833 :: ('2067', 'Gene') :: ['ERCC1'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity4735 :: ('2068', 'Gene') :: ['XPD'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['CBDCA', 'carboplatin'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity20823 :: ('7517', 'Gene') :: ['XRCC3'] @entity1950 :: ('MESH:C536962', 'Disease') :: ['TS'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity3003 :: (MESH:D016190,Chemical) :: ['Carboplatin']
